Malignant Glioma of Brain
14
1
3
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
7.1%
1 terminated out of 14 trials
80.0%
-6.5% vs benchmark
14%
2 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (14)
Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma
Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA）
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Pilot Immunotherapy Trial for Recurrent Malignant Gliomas
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas
Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas
LITT Palliative Treatment for Patients With Malignant Gliomas
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
Panitumumab and Irinotecan for Malignant Gliomas
ADV-TK Improves Outcome of Recurrent High-Grade Glioma